NCT00872196

A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies

A Follow-up Study to Assess the Evolution and Persistence of Resistance to ABT-072 After Discontinuation of ABT-072 Therapy in HCV Genotype-1 Infected Subjects Who Participated in Phase 1, 2, or 3 ABT-072 Clinical Studies

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: AbbVie (prior sponsor, Abbott) · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a follow-up study with no treatment and only samples being collected.

Detailed description

The purpose of this study is to evaluate the development of specific viral mutations in response to treatment with ABT-072.

Conditions

• Hepatitis C Virus Infection

Interventions

Type	Name	Description
DRUG	ABT-072	Blood samples are being taken from subjects previously treated with ABT-072.

Timeline

• Start date: 2009-04-01
• Primary completion: 2010-04-01
• Completion: 2010-04-01
• First posted: 2009-03-31
• Last updated: 2013-04-01

Locations

1 site across 1 country: United States